buy MK-1775 yellow powder with female ovarian cancer effective treatment Â
Quick Details of MK-1775
Product Name: MK-1775
Product Name: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]
pyrimidin-3(2H)-one
Synonyms: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3
(2H)-one;MK-1775;MK-1775,MK1775;2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-
dihydropyrazolo[3,4-d]pyrimidin-3-one;2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-
1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one MK 1775;MK 1775 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-
yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775, >=98%;MK-1175
CAS: 955365-80-7
MF: C27H32N8O2
MW: 500.59538Â
purity:99.57%
shipping methods:EMS,TNT,UPS,FEDEX,DHL
payment methods:westeron union,bitcoins,bank transfer,moneygram.
Speciafications of Mk-1775
Formal Name
1,2-dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-3H-pyrazolo[3,4-d]pyrimidin-3-one
CAS Number
955365-80-7
Synonyms
AZD 1775
Molecular Formula
CÂ 27Â HÂ 32Â NÂ 8Â OÂ 2
Formula Weight
500.6
Purity
≥98%
Formulation
A crystalline solid
λmax
229, 257, 292 nm
SMILES
CN1CCN(C2=CC=C(NC3=NC=C(C(N(CC=C)N4C5=CC=CC(C(C)(O)C)=N5)=O)C4=N3)C=C2)CC1
InChI Code
InChI = 1 S / C 27 H 32 N 8 O 2 / c 1 -5 - 13 - 34 - 25 (36) 21-18-28-26 (29-19-9-11-20 (12-10-19) 33-16-14-32 4) 15-17-33) 31-24 (21) 35 (34) 23-8-6-7-22 (30-23) 27 (2,3) 37 / h5-12, 18, 37H, 1, 13 - 17 H 2, 2 - 4 H 3, (H, 28, 29, 31)
InChI Key
BKWJAKQVGHWELA-UHFFFAOYSA-N
Detailed Descriptions of Mk-1775
Synonyms AZD 1775
MK-1775 is an inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM).1 It has been shown to inhibit the phosphorylation of Cdc2 at
tryosine-15, which abrogates the G2 DNA damage checkpoint.1 In p53-deficient tumors that rely solely on the G2 checkpoint upon DNA
damage, MK-1775, in combination with DNA-damaging chemotherapeutic agents, is reported to induce apoptosis in vitro and potentiate
the inhibition of tumor growth in vivo.1
More detailed introductions of MK-1775
MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells.
in vivo: MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models models is also moderate.
Â